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The utilization of the dendritic cell as an immunological modality for the cancer 
immunotherapy was enabled due to the finding of their major function in antigen presentation 
and also due to the induction of the primary immune response through the activation of the 
naive T-cells. 
The tumour cells from the cell lines killed by the high hydrostatic pressure are a suitable 
source of the antigens. This hydrostatic pressure induces an immunogenic cell death and 
provides an effective activation of immune responses. 
The objectives of this thesis are to describe the recent findings of the ovarian cancer 
immunotherapy. It is focused on dendritic cell based vaccine and on assessing the possible 
step for the optimization of the manufacturing protocol of this vaccine. 
Within the experimental part, I followed the kinetics of the immunogenic parameters in the 
tumour cells line SKOV3 of ovarian cancer which were treated by application of high 
hydrostatic pressure, the inducer of immunogenic cell death. The results have been analysing 
at different time intervals and they have led to verification of the possibility of storing the 
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